Breaking News Instant updates and real-time market news.

FTR

Frontier Communications

$7.72

0.29 (3.90%)

, UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$8.67

-0.11 (-1.25%)

08:45
01/12/18
01/12
08:45
01/12/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Frontier Communications (FTR) 26.38% +0.12, ProShares Ultra VIX Short Term Futures (UVXY) 16.90% +0.11, Xunlei (XNET) 29.60% +0.07, (QD) 62.17% +0.06, Gold Bear 3x (DUST) 8.37% +0.05, Pandora (P) 1.09% +0.01, Yamana Gold (AUY) 0.58% +0.01, and iPath S&P 500 VIX Short Term Futures (VXX) 2.79% +0.01.

FTR

Frontier Communications

$7.72

0.29 (3.90%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$8.67

-0.11 (-1.25%)

XNET

Xunlei

$22.90

0.51 (2.28%)

QD

Qudian

$12.18

0.2 (1.67%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$23.19

-0.36 (-1.53%)

P

Pandora

$4.57

0.04 (0.88%)

AUY

Yamana Gold

$3.34

0.16 (5.03%)

VXX

iPath S&P 500 VIX Short-Term Futures

$25.84

-0.15 (-0.58%)

  • 16

    Feb

  • 27

    Feb

FTR Frontier Communications
$7.72

0.29 (3.90%)

12/13/17
MSCO
12/13/17
NO CHANGE
Target $21.6
MSCO
Overweight
Morgan Stanley says CenturyLink can outperform after industry's challenging 2017
Noting that 2017 was a challenging year for wireline telecom and that CenturyLink struggled to hit guidance for the third consecutive year, Simon Flannery still believes that the Level 3 merger is transformative and contends that CenturyLink's (CTL) valuation should ultimately diverge from legacy wireline peers such as Frontier (FTR) and Windstream (WIN) if the deal proves successful. If 2017 marks the trough in operational performance, CenturyLink is poised to outperform "meaningfully" next year and beyond, said Flannery, who trimmed his price target on the stock to $21.60 from $26 but maintains an Overweight rating on the shares.
12/15/17
LEHM
12/15/17
INITIATION
Target $7
LEHM
Underweight
Frontier Communications initiated with an Underweight at Barclays
Barclays analyst Amir Rozwadowski started Frontier Communications with an Underweight rating and $7 price target. The analyst believes the company's dividend is at risk of being cut further over the near term.
12/15/17
12/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Simon Flannery started ViaSat (VSAT) with an Equal Weight rating and $78 price target. 2. Cantor Fitzgerald analyst Elemer Piros initiated Rigel Pharmaceuticals (RIGL) with an Overweight rating and $6 price target, sayign the company is poised to achieve FDA approval of fostamatinib for lead indication immune thrombocytopenia. 3. Exelon (EXC) analyst Paul Fremont initiated Exelon with an Underperform and $36 price target to reflect expected earnings pressure from weak forward gas and power prices and high debt. 4. Credit Suisse analyst Gregory Lewis started Ocean Rig UDW (ORIG) with an Outperform rating and $32 price target, stating that the company's restructuring wiped away $3.3B in debt. 5. Barclays analyst Amir Rozwadowski started Frontier Communications (FTR) with an Underweight rating and $7 price target, as he believes the company's dividend is at risk of being cut further over the near term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/17
11/10/17
DOWNGRADE
Target $4

Underperform
Frontier Communications downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst David Barden downgraded Frontier Communications to Underperform and slashed its price target to $4 from $19 due to dividend concerns. Barden said Frontier is evaluating the dividend quarter to quarter, while trying to reduce net leverage, and cannot assume with certainty that the dividends will get paid.
UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$8.67

-0.11 (-1.25%)

XNET Xunlei
$22.90

0.51 (2.28%)

QD Qudian
$12.18

0.2 (1.67%)

11/24/17
SBSH
11/24/17
NO CHANGE
Target $38.79
SBSH
Buy
Qudian user growth to see limited impact from new rules, says Citi
Citi analyst Daphne Poon believes Alipay's new annualized rate cap of 24% will have a limited impact on Qudian's user growth. The analyst sees pressure on new user growth being "relatively limited" given Qudian's "strong brand recognition, large existing user base, and strong consumption scenario." Poon believes the company enjoys stronger borrower engagement ability than peers. The analyst does, however, see more potential for an earnings hit from the lower APR on loans facilitated via Alipay, especially for first time borrowers. If 20% of Qudian's loan volume is originated from Alipay and subject to the 24% APR cap, it will lower Qudian's 2018 earnings net profit after tax by 10%, the analyst tells investors in a research note. Poon keeps a Buy rating on Qudian with a $38.79 price target.
11/24/17
MACQ
11/24/17
NO CHANGE
Target $24
MACQ
Outperform
Qudian price target lowered to $24 from $36 at Macquarie
Macquarie analyst Dexter Hsu lowered his price target for Qudian shares to $24 after Ant Financial asked the company and its peers to cap the annual percentage rate at 24%, below the 34% charged by Qudian, from the end of this month if they would like to stay in the ecosystem. While Alipay still accounts for two-thirds of Qudian's loans facilitated, the impact could be smaller than expected since the company has been directing users to its own app, where the annual percentage rate will stay at 36%, Hsu tells investors in a research note. Nonetheless, he cut his 2017, 2018, 2019 and 2020 earnings estimates by 8%, 23%, 32% and 39%, respectively. The analyst keeps an Outperform rating on Qudian shares.
11/27/17
STFL
11/27/17
NO CHANGE
Target $19
STFL
Buy
Qudian price target lowered to $19 from $35 at Stifel
Stifel analyst John Davis estimates Alipay's recently announced rate cap could result in as much as a 25% earnings hit to Qudian, but he also believes in that context that the more than 50% correction in the stock is overdone. Headlines about a data leak/breach are unconfirmed, added Davis, who cut his price target on Qudian shares to $19 from $35 but maintains a Buy rating on the stock.
12/05/17
NEED
12/05/17
NO CHANGE
NEED
Qudian price target lowered to $20 from $30 at Needham
Needham analyst Mayank Tandon lowered his price target on Qudian shares to $20 from $30, noting recent news that could create near-term headwinds for the company, including Ant Financial announcing a 24% APR cap for all third-party credit services on its Alipay interface, and PBOC and CRBC releasing a new regulation notice that outlined principles and additional guidelines related to the cash loan business in China. Despite these potential headwinds, Tandon believes Qudian's fundamentals remain in tact, and maintained a Buy rating on Qudian shares.
DUST Direxion Daily Gold Miners Bear 3X ETF
$23.19

-0.36 (-1.53%)

P Pandora
$4.57

0.04 (0.88%)

01/08/18
01/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GoPro (GPRO) downgraded to Neutral from Buy at Longbow with analyst Joe Wittine saying his channel checks confirmed the holidays missed the company's plan and late quarter $100 price cuts were not enough to save the quarter. 2. Snap (SNAP) downgraded to Hold from Buy at Jefferies with analyst Brent Thill saying he continues to have optimism around Snap's platform, but believes "fundamental execution needs to be shown" before he can be more positive on the name. 3. Cirrus Logic (CRUS) downgraded to Sector Weight from Overweight at KeyBanc with analyst John Vinh citing his "disappointment" with the current iPhone cycle and the lack of meaningful content gains until 2019. 4. Pandora (P) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Benjamin Swinburne noting that the company's core free product has not evolved meaningfully and faces continued innovation by Spotify, Apple (AAPL) and Amazon (AMZN) while also being pressured by free music available on Google's (GOOG) YouTube. 5. GrubHub (GRUB) downgraded to Neutral from Outperform at Wedbush with analyst Aaron Turner saying that while he continues to like the company's market opportunity and competitive positioning, the current peak valuation of shares accurately reflects these positive dynamics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
MSCO
01/08/18
DOWNGRADE
Target $6
MSCO
Equal Weight
Pandora downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne downgraded Pandora (P) to Equal Weight from Overweight, noting that the company's core free product has not evolved meaningfully and faces continued innovation by Spotify, Apple (AAPL) and Amazon (AMZN) while also being pressured by free music available on Google's (GOOG) YouTube. While engagement is challenged, is increasingly clear that consumers' willingness to accept more ads is limited, which also puts pressure on monetization and means growing ad revenue in 2018 is "no longer a given," he tells investors. Swinburne lowered his price target on Pandora shares to $6 from $12.
01/02/18
RHCO
01/02/18
NO CHANGE
Target $7
RHCO
Hold
Pandora 2018 EBITDA consensus is too high, says SunTrust
SunTrust analyst Matthew Thornton lowered his price target on Pandora (P) to $7 from $8 and kept his Hold rating, saying that while he is positive on the company's initiatives to boost User Hours and Subscriptions, they will take time and investment to materialize. Thornton says the consensus EBITDA view of -$42M is too high, given the expected rise in costs. The analyst also points to "intense" competition in streaming music as well as potential entry in the space at Facebook (FB), based on its music hires and content licensing.
12/12/17
PIPR
12/12/17
NO CHANGE
Target $9
PIPR
Overweight
Piper likes Pandora risk/return at current share levels
After traveling with management, Piper Jaffray analyst Stan Meyers says he likes risk/return profile of Pandora Media shares at current levels. The analyst left the meetings "more comfortable with the evolving Pandora story." He sees improving monetization, listenership growth and cost reductions driving Pandora's growth. The analyst reiterates an Overweight rating on the shares with a $9 price target.
AUY Yamana Gold
$3.34

0.16 (5.03%)

02/22/17
BOFA
02/22/17
DOWNGRADE
BOFA
Underperform
Yamana Gold downgraded to Underperform from Neutral at BofA/Merrill
01/13/17
FBCO
01/13/17
DOWNGRADE
Target $4
FBCO
Neutral
Yamana Gold downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Anita Soni downgraded Yamana Gold to Neutral and lowered its price target to $4 from $4.50 due to valuation and revised estimates for El Penon due to higher costs and higher production forecasts.
VXX iPath S&P 500 VIX Short-Term Futures
$25.84

-0.15 (-0.58%)

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.